Product image of Lenalidomide Ariti (Lenalidomide) supplied by GNH India

Lenalidomide Ariti

Active Ingredient:
Lenalidomide
Origin:
EU

Lenalidomide Ariti (Lenalidomide)

Lenalidomide, the active ingredient in Lenalidomide Ariti, is an immunomodulatory drug presented as an oral formulation for oral use. It treats multiple myeloma and myelodysplastic syndromes with del(5q) chromosome abnormality in adult patients.
GNH India supplies Lenalidomide Ariti as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Ariti Sa

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Lenalidomide is an immunomodulatory agent indicated for specific hematologic cancers.

  • Multiple myeloma (newly diagnosed): improves progression‑free survival when combined with dexamethasone.
  • Multiple myeloma (relapsed/refractory): extends overall survival in combination regimens.
  • Myelodysplastic syndromes with del(5q): reduces transfusion dependence and may improve peripheral blood counts.

How It Works

  • Lenalidomide binds to the cereblon component of the CRL4 E3 ubiquitin ligase complex, altering substrate specificity. This leads to ubiquitination and proteasomal degradation of transcription factors such as Ikaros and Aiolos, resulting in anti‑angiogenic, immunomodulatory, and direct anti‑tumor effects that inhibit malignant plasma cell proliferation.

Side Effects

Lenalidomide may cause a range of adverse reactions, which are categorized by frequency.

Common Side Effects

  • Fatigue: persistent tiredness reported by many patients.
  • Neutropenia: reduced neutrophil count increasing infection risk.
  • Thrombocytopenia: lowered platelet levels that may cause bruising.
  • Diarrhea: loose stools occurring during treatment.
  • Rash: skin eruptions of varying intensity.
  • Constipation: difficulty passing stool.

Serious or Rare Side Effects

  • Venous thromboembolism: blood clots in deep veins or lungs.
  • Severe neutropenia: profound drop in neutrophils leading to serious infections.
  • Severe thrombocytopenia: markedly low platelets causing bleeding.
  • Secondary primary malignancies: emergence of new cancers.
  • Hepatic toxicity: liver enzyme elevations or injury.
  • Severe allergic reactions: anaphylaxis or Stevens‑Johnson syndrome.

Precautions & Warnings

Before initiating therapy, clinicians should consider several safety measures.

  • Pregnancy contraindication: drug is category X and must not be used during pregnancy.
  • Thrombosis risk: assess patient history and consider prophylactic anticoagulation.
  • Hematologic monitoring: perform regular CBC to detect neutropenia or thrombocytopenia.
  • Renal function: adjust dose in patients with impaired renal clearance.
  • Drug interactions: avoid concomitant use with strong CYP3A4 inhibitors.
  • Store at below 25°C: keep in the original pack, protect from moisture.

Avoid Interactions

Lenalidomide can interact with other medicines, requiring careful management.

Major Interactions (Avoid)

  • Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase lenalidomide exposure and toxicity.
  • Concurrent use with anticoagulants (e.g., warfarin) without monitoring: heightened risk of bleeding.
  • Combination with other immunomodulatory agents: may amplify hematologic toxicity.

Moderate Interactions (Monitor Closely)

  • CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce lenalidomide efficacy.
  • Non‑steroidal anti‑inflammatory drugs (NSAIDs): can affect renal function and increase bleeding risk.
  • Live vaccines: immunosuppression may reduce vaccine efficacy.

Frequently Asked Questions

Lenalidomide Ariti is prescribed for the treatment of multiple myeloma, both in newly diagnosed and relapsed/refractory settings, and for myelodysplastic syndromes that carry the del(5q) chromosomal abnormality. In these conditions it helps control disease progression and may reduce the need for blood transfusions.

Lenalidomide binds to cereblon, a component of the CRL4 E3 ubiquitin ligase complex, changing its substrate specificity. This triggers degradation of specific transcription factors, leading to anti‑angiogenic effects, modulation of the immune response, and direct inhibition of malignant cell growth.

The dose of Lenalidomide Ariti is individualized by the prescribing physician based on the patient’s diagnosis, disease stage, renal function, and other clinical factors. Physicians determine the appropriate strength, schedule, and any dose adjustments needed throughout therapy.

Lenalidomide is classified as pregnancy category X, meaning it is contraindicated during pregnancy because of a high risk of fetal harm. Women of child‑bearing potential must use effective contraception, and breastfeeding is not recommended while taking the drug.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Lenalidomide belongs to the immunomodulatory drug (IMiD) class, similar to thalidomide but with a more favorable safety profile and stronger anti‑myeloma activity. Compared with thalidomide, lenalidomide generally causes less peripheral neuropathy and offers greater efficacy when combined with dexamethasone.

Store Lenalidomide Ariti at temperatures below 25 °C in its original container, protecting it from moisture and direct sunlight. Keep the product out of reach of children and avoid crushing or splitting tablets unless specifically instructed by a pharmacist.

Lenalidomide Ariti is taken orally, usually once daily on a scheduled cycle. It may be taken with or without food, but patients should follow the specific instructions provided by their healthcare professional to maintain consistent absorption.

The most serious risks include severe neutropenia or thrombocytopenia, which can lead to infections or bleeding, and venous thromboembolism such as deep‑vein thrombosis or pulmonary embolism. Patients should be monitored regularly for blood‑count changes and signs of clot formation.

Lenalidomide Ariti should not be used by pregnant women, individuals with known hypersensitivity to lenalidomide or its excipients, and patients with severe renal impairment unless dose adjustments are made. It is also contraindicated in patients with uncontrolled active infections.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Lenalidomide

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT